<DOC>
	<DOC>NCT01233622</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of vildagliptin 50 mg bid as add-on therapy to metformin plus glimepiride in patients with Type 2 Diabetes (T2D).</brief_summary>
	<brief_title>Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criteria Confirmed diagnosis of T2DM by standard criteria. Treatment with oral antidiabetic therapy, on stable dose for at least 12 weeks prior to the screening visit. Acceptable background antidiabetic therapy includes: metformin (≥ 1500 mg) as monotherapy or in combination with SU, TZDs, or glinides Age: ≥18 to ≤ 80 years HbA1c of ≥ 7.5 and ≤ 11.0% Body Mass Index (BMI) ≥22 to ≤45 kg/m2 Exclusion criteria: FPG ≥ 270 mg/dL (≥ 15.0 mmol/L) Acute metabolic diabetes complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months Any of following within past 6 months: Myocardial infarction, TIA or stroke, coronary artery bypass surgery or percutaneous coronary intervention History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes Acute infections which may affect blood glucose control within 4 weeks prior to screening Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>